LightNews LightNews
dawndone.bsky.social
@dawndone.bsky.social
330 followers 550 following 160 posts
Posts Replies Media Videos
Reposted
helenkennedy.bsky.social
Ten? More like 17!
December 10, 2025 at 4:10 PM
Reposted
sailorrooscout.bsky.social
In a breakthrough that could potentially rewrite the prevention and treatment of cancer, researchers have discovered how certain immune cells can break through tumors’ defenses. They have also developed a new nanoscale vaccine that shows promise in preventing cancers from occurring in the first
December 9, 2025 at 5:03 PM
Reposted
sailorrooscout.bsky.social
Melanoma, pancreatic cancer, and triple-negative breast cancer (TNBC) are each serious clinical challenges due to how common or aggressive they are and how poorly they often respond to treatment. Which is why researchers are determined to develop an effective treatment for all of them.
December 9, 2025 at 5:03 PM
Reposted
sailorrooscout.bsky.social
Researchers envision their vaccine being used as both a treatment and a preventive, and as an approach to treating multiple cancer types. NOTE: This is PRECLINICAL.
• www.umass.edu/news/article...

The study has been published in Cell. YES, it is PEER-REVIEWED.
• www.cell.com/cell-reports...

🧪🧵⬇️
HIGHLIGHTS • Lipid NPs carrying STING and TLR4 agonists promote synergistic type I interferons • NPs drain efficiently to lymph nodes and increase polyfunctional T and B cells • NPs improve tumor-free outcomes with memory against multiple aggressive tumor models SUMMARY We report on the utility of a "super-adjuvant" nanoparticle (NP) system as a modular, customizable platform for next-generation cancer vaccination. Using nanomaterials engineering technology, we aim to harness not only the effective adjuvanticity of whole-pathogen vaccines, but also the safety of subunit vaccines. Our lipid-based NP platform co-encapsulates agonists of the stimulator of interferon genes (STING) and Toll-like receptor 4 (TLR4) pathways to promote synergistic production of type I interferons and other proinflammatory cytokines in innate antigen-presenting dendritic cells and macrophages. Compared to empty NPs and free agonists, dual-adjuvant NPs administered with antigenic peptides or tumor cell lysate promote increased antigen processing and presentation, drain efficiently to nearby lymph nodes, increase polyfunctional tumor-specific T and B cells, and improve tumor-free outcomes upon vaccination and subsequent challenge with multiple aggressive tumor cells. Graphical Abstract The vaccine combines two immune-stimulating molecules (adjuvants) in a tiny lipid nanoparticle that enhances both innate and adaptive immune responses. The innate immune system acts as the body’s first line of defense, responding quickly and non-specifically to invaders using cells that release inflammatory signals. The adaptive immune system takes longer to activate but provides a targeted, long-lasting response, training T-cells and B- cells to recognize and remember specific threats. Together, they form a coordinated defense: the innate system alerts and activates the adaptive system, which then delivers precise and durable immunity.
December 9, 2025 at 5:02 PM